Free Trial

BMY Stock Gets Stronger EPS Estimate from Zacks Research

Bristol Myers Squibb logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised its Q3 2027 EPS estimate for Bristol Myers Squibb to $1.74 from $1.55, while maintaining a Hold rating.
  • Bristol Myers reported quarterly EPS of $1.35, beating the $1.10 consensus, and revenue of $13.07 billion, up 6.9% year over year.
  • Analyst sentiment remains broadly cautious: MarketBeat’s consensus rating is Hold, with an average price target of $65.46.
  • MarketBeat previews the top five stocks to own by December 1st.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Zacks Research raised their Q3 2027 earnings per share estimates for shares of Bristol Myers Squibb in a research note issued to investors on Wednesday, November 11th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $1.74 per share for the quarter, up from their previous forecast of $1.55. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb's FY2027 earnings at $6.41 EPS, Q1 2028 earnings at $1.36 EPS, Q2 2028 earnings at $1.25 EPS and Q3 2028 earnings at $1.16 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the prior year, the firm posted $1.63 EPS. The firm's revenue for the quarter was up 6.9% compared to the same quarter last year.

BMY has been the subject of a number of other research reports. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Guggenheim restated a "buy" rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 target price on the stock. Finally, BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and an average price target of $65.46.

View Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Price Performance

Shares of BMY opened at $63.39 on Monday. The company has a market cap of $129.57 billion, a price-to-earnings ratio of 14.06, a PEG ratio of 0.33 and a beta of 0.20. Bristol Myers Squibb has a 1-year low of $45.26 and a 1-year high of $68.64. The company's fifty day simple moving average is $61.90 and its 200 day simple moving average is $60.31. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Pinion Investment Advisors LLC increased its position in Bristol Myers Squibb by 3.8% during the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company's stock valued at $269,000 after purchasing an additional 158 shares during the period. Altura Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 1.2% in the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company's stock worth $856,000 after purchasing an additional 161 shares during the period. Capital City Trust Co. FL lifted its position in shares of Bristol Myers Squibb by 0.7% in the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company's stock worth $1,455,000 after purchasing an additional 167 shares during the period. Eagle Bay Advisors LLC lifted its position in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company's stock worth $408,000 after purchasing an additional 168 shares during the period. Finally, Blue Bell Private Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 21.1% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 169 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.88%.

More Bristol Myers Squibb News

These are some of the BMY news items that stood out recently:

  • Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
  • Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
  • Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Stories

Earnings History and Estimates for Bristol Myers Squibb (NYSE:BMY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bristol Myers Squibb Right Now?

Before you consider Bristol Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.

While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines